Equibles does not estimate personal net worth.
Get an email with a short summary when Pulse Biosciences, Inc. publishes a filing, an earnings call transcript or a press release.
Get PLSE alertsJon Skinner is recorded as CFO at Pulse Biosciences, Inc. (PLSE). Pulse Biosciences, Inc. reported in an 8-K filed February 4, 2025 that Jon Skinner was appointed Chief Financial Officer, effective February 3, 2025. The proxy statement of Pulse Biosciences, Inc. reports total compensation of $2,843,000 for Jon Skinner in fiscal 2025, including a base salary of $366,667. Disclosed compensation is on record for 4 fiscal years. Jon Skinner has spoken on 6 earnings calls and 1 other investor event across 1 company, most recently for Pulse Biosciences, Inc. on August 6, 2026. Pulse Biosciences, Inc. is classified in the Medical Instruments & Supplies industry within the Healthcare sector. Other leadership on record at Pulse Biosciences, Inc. includes Burke T. Barrett (CEO and Board Member), Kevin Danahy (CEO), Paul A. LaViolette (CEO, Chairman and Board Member) and 7 others.
“Pulse Biosciences, Inc. (the "Company") has appointed Jon Skinner as Chief Financial Officer of the Company, effective as of February 3, 2025 (the "Start Date").”
“I encourage listeners to review today's earnings release for a detailed reconciliation of non-gap measures to the most comparable gap measures. In the second quarter, we generated revenue of $434,000 and costs of product revenue was $273,000 for the quarter.”
“I encourage listeners to review Monday's earnings release for a detailed reconciliation of non-GAAP measures to the most comparable GAAP measures. In the first quarter, we generated revenues comprised of both impulse capital and Vibrance disposable sales.”
“So we had $80 million in cash at the end of 2025. And as you mentioned, we had a $60 million ATM that is in place, as well as a $200 million shelf registration that we put in place.”
“Now I will highlight our GAAP and non-GAAP financial results before providing commentary on future cash use. I encourage listeners to review today's earnings release for a detailed reconciliation of non-GAAP measures to the most comparable GAAP measures.”
“Now I will highlight our GAAP and non-GAAP financial results before providing commentary on future cash use and revenue. I encourage listeners to review today's earnings release for a detailed reconciliation of non-GAAP measures to the most comparable GAAP measures.”
Medical Instruments & Supplies · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Pulse Biosciences, Inc. (PLSE) | Chief Financial Officer | $366,667 | $2,843,000 |
| 2024 | Pulse Biosciences, Inc. (PLSE) | Chief Financial Officer | — | — |
| 2023 | Pulse Biosciences, Inc. (PLSE) | Chief Financial Officer | — | — |
| 2022 | Pulse Biosciences, Inc. (PLSE) | Chief Financial Officer | — | — |
